fluorodopa f 18 has been researched along with Parkinsonian Disorders in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Berman, KF; Eisenberg, DP; Gregory, MD; Lopez, G; Sidransky, E | 1 |
| Chaves, LT; De Jong, BM; Dierckx, RAJO; Doorduin, J; Kremer, BPH; Leenders, KL; Stormezand, GN; Vállez García, D | 1 |
| Mittal, BR; Modi, M; Shree, R; Shukla, J; Sood, A; Vatsa, R | 1 |
| Checkoway, H; Criswell, SR; Flores, HP; Huang, J; Moerlein, SM; Nielsen, SS; Perlmutter, JS; Racette, BA; Seixas, N; Sheppard, L; Warden, M | 1 |
| Arbizu, J; Collantes, M; DiCaudo, C; Luquin, MR; Marcilla, I; Ordóñez, C; Peñuelas, I; Riverol, M | 1 |
| Benisvy, D; Darcourt, J; Dufour, M; Fontana, X; Koulibaly, PM; Ouvrier, MJ; Sapin, N; Schiazza, A | 1 |
| Schwarz, J | 1 |
| Forsback, S; Johansson, J; Joutsa, J; Kaasinen, V; Martikainen, K; Niemelä, S; Rinne, JO | 1 |
| Dinelle, K; Farrer, MJ; Holden, JE; Kornelsen, R; Mah, C; McCormick, S; Sossi, V; Stoessl, AJ; Walker, MD | 1 |
| Breakefield, XO; Calne, DB; Hedrich, K; Klein, C; Leung, J; Lieberman, A; Nausieda, PA; Pal, PK; Samii, A; Stoessl, AJ | 1 |
| Breeze, R; Dhawan, V; Eidelberg, D; Fahn, S; Feigin, A; Freed, C; Fukuda, M; Greene, P; Ma, Y; Shi, Q | 1 |
| Chen, CY; Chou, YH; Huang, WS; Liu, JC; Liu, RS; Ma, KH | 1 |
| Al-Rashid, I; Angeles Mena, M; Castilla, C; Cools, A; Eshuis, S; Fontan, A; Garcia de Yebenes, J; Gonzalo, I; Hernández, I; Leenders, K; López, I; Maguire, P; Perez Higueras, A; Pruim, J; Rabano, A; Rojo, A; Sanchez Albisua, J; Sanchez Pernaute, R | 1 |
| Aebischer, P; Bloch, J; Condé, F; Dauguet, J; Déglon, N; Dollé, F; Hantraye, P; Hinnen, F; Kishima, H; Palfi, S; Poyot, T; Pralong, W | 1 |
| Allen, RC; Cornfeldt, ML; Doudet, DJ; Honey, CR; Schweikert, AW | 1 |
| Ametamey, SM; Blagoev, M; Hengerer, B; Hintermann, S; Honer, M; Schubiger, PA; Waldmeier, P | 1 |
| Chen, W; Seibyl, JP; Silverman, DH | 1 |
| Abe, Y; Ito, K; Kachi, T; Kato, T; Sobue, G; Yanagisawa, N | 1 |
| Aebischer, P; Bloch, J; Brown, WD; Carvey, P; Chen, EY; Chu, Y; Déglon, N; Emborg, ME; Hantraye, P; Holden, JE; Kordower, JH; Leventhal, L; Ling, Z; Ma, SY; McBride, J; Palfi, S; Pyzalski, R; Roitberg, BZ; Taylor, MD; Trono, D | 1 |
| Andersen, F; Bender, D; Cumming, P; Danielsen, EH; Falborg, L; Gillings, N; Gjedde, A; Marthi, K; Munk, O; Møller, A; Smith, D; Steffensen, E; Sørensen, JC; Vafaee, M | 1 |
| Cumming, P; Doudet, D; Munk, OL | 1 |
| Barrio, JR; Delanney, LE; Delfani, K; Farahani, KF; Huang, SC; Irwin, I; Janson, AM; Langston, JW; Milonas, C; Phelps, ME; Satyamurthy, N; Shoghi-Jadid, K; Stout, DB; Togasaki, DM; Yee, RE | 1 |
| Broussolle, E; Guillouet, S; Thobois, S | 1 |
4 review(s) available for fluorodopa f 18 and Parkinsonian Disorders
| Article | Year |
|---|---|
18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Humans; Image Processing, Computer-Assisted; Parkinsonian Disorders; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Time Factors | 2014 |
[Nuclear medicine imaging in patients with Parkinson's syndrome: an update].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Energy Metabolism; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Humans; Nerve Degeneration; Neurons; Parkinson Disease; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Dopamine; Regional Blood Flow; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2010 |
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Topics: Adrenal Gland Neoplasms; Amino Acids; Brain Neoplasms; Caudate Nucleus; Dihydroxyphenylalanine; Fluorine Radioisotopes; Glioma; Humans; Movement Disorders; Neuroendocrine Tumors; Parkinsonian Disorders; Positron-Emission Tomography; Putamen; Radiopharmaceuticals | 2007 |
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantation; Cerebrovascular Circulation; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agonists; Electric Stimulation Therapy; Fetal Tissue Transplantation; Forecasting; Genetic Predisposition to Disease; Humans; Iatrogenic Disease; Imagination; Ligands; Mesencephalon; Motor Activity; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Radiopharmaceuticals; Rats; Receptors, Dopamine; Risk; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tremor | 2001 |
1 trial(s) available for fluorodopa f 18 and Parkinsonian Disorders
| Article | Year |
|---|---|
Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.
Topics: Adult; Brain; Caudate Nucleus; Cohort Studies; Dihydroxyphenylalanine; Double-Blind Method; Dyskinesias; Fetal Tissue Transplantation; Fluorine Radioisotopes; Humans; Middle Aged; Parkinsonian Disorders; Putamen; Tomography, Emission-Computed | 2002 |
18 other study(ies) available for fluorodopa f 18 and Parkinsonian Disorders
| Article | Year |
|---|---|
Comparison of Transcranial Sonography and [
Topics: Dihydroxyphenylalanine; Dopamine; Glucosylceramidase; Humans; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Ultrasonography | 2022 |
Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
Topics: Aged; Caudate Nucleus; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroimaging; Parkinson Disease; Parkinsonian Disorders; Positron-Emission Tomography; Putamen; Retrospective Studies | 2020 |
Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor.
Topics: Dihydroxyphenylalanine; Essential Tremor; Female; Humans; Male; Middle Aged; Organotechnetium Compounds; Parkinson Disease; Parkinsonian Disorders; Positron Emission Tomography Computed Tomography; Single Photon Emission Computed Tomography Computed Tomography; Tropanes | 2021 |
[
Topics: Adult; Corpus Striatum; Cross-Sectional Studies; Dihydroxyphenylalanine; Female; Humans; Magnetic Resonance Imaging; Male; Manganese Poisoning; Middle Aged; Occupational Diseases; Occupational Exposure; Parkinsonian Disorders; Positron-Emission Tomography; Welding | 2018 |
Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neural Pathways; Parkinsonian Disorders; Positron-Emission Tomography; Substantia Nigra | 2014 |
Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders.
Topics: Aged; Compulsive Behavior; Dihydroxyphenylalanine; Disruptive, Impulse Control, and Conduct Disorders; Frontal Lobe; Humans; Male; Middle Aged; Parkinsonian Disorders | 2012 |
In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radioisotopes; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tomography, Emission-Computed | 2013 |
[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
Topics: Adolescent; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; DNA Mutational Analysis; Dominance, Cerebral; Gene Expression; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Ligases; Male; Neurologic Examination; Parkinsonian Disorders; Putamen; Tomography, Emission-Computed; Ubiquitin-Protein Ligases | 2002 |
99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Macaca; Metabolic Clearance Rate; Models, Animal; Organotechnetium Compounds; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Reference Values; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tropanes | 2003 |
Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates.
Topics: Animals; Cell Count; Dihydroxyphenylalanine; Dopamine; Fibroblast Growth Factor 2; Fluorine Radioisotopes; Glial Cell Line-Derived Neurotrophic Factor; Macaca fascicularis; Nerve Growth Factors; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Severity of Illness Index; Tyrosine 3-Monooxygenase | 2002 |
Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons.
Topics: Animals; Capsules; Dihydroxyphenylalanine; Fluorine Radioisotopes; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Lateral Ventricles; Magnetic Resonance Imaging; Male; Motor Activity; Nerve Growth Factors; Neuroglia; Neurons; Papio; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Tomography, Emission-Computed; Tyrosine 3-Monooxygenase | 2004 |
PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.
Topics: Animals; Binding, Competitive; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Female; Humans; Macaca fascicularis; Macaca mulatta; Male; Parkinsonian Disorders; Pigment Epithelium of Eye; Putamen; Raclopride; Radioligand Assay; Recovery of Function; Tomography, Emission-Computed; Treatment Outcome; Up-Regulation | 2004 |
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Male; Mice; Mice, Inbred C57BL; Neurotransmitter Agents; Nortropanes; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Substantia Nigra; Synaptic Transmission; Tyrosine | 2006 |
[Diagnostic utility of positron emission tomography for parkinsonism after chronic manganese exposure].
Topics: Diagnosis, Differential; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Male; Manganese Poisoning; Middle Aged; Occupational Exposure; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Lentivirus; Macaca mulatta; Neostriatum; Nerve Degeneration; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Parkinson Disease; Parkinsonian Disorders; Psychomotor Performance; Substantia Nigra; Tyrosine 3-Monooxygenase | 2000 |
Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts.
Topics: Animals; Antineoplastic Agents; Dihydroxyphenylalanine; Dopamine; Graft Survival; Isoquinolines; Parkinsonian Disorders; Receptors, Dopamine; Regional Blood Flow; Swine; Tomography, Emission-Computed; Visual Cortex | 2001 |
Loss of metabolites from monkey striatum during PET with FDOPA.
Topics: Animals; Blood-Brain Barrier; Denervation; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Fluorine Radioisotopes; Macaca mulatta; Neostriatum; Parkinsonian Disorders; Tomography, Emission-Computed | 2001 |
Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Female; Fluorine Radioisotopes; Male; Neural Pathways; Neurotoxins; Parkinsonian Disorders; Saimiri; Substantia Nigra; Tomography, Emission-Computed | 2001 |